SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as traders debate whether the recent dip represents a buying opportunity or the start of a longer correction, with some pointing to potential bearish signals while others cite strong underlying fundamentals and institutional interest. Community discussions revolve around key support levels, the influence of Michael Saylor's MicroStrategy, and comparisons to past market cycles. Bullish investors are hoping to trigger a short squeeze.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending due to the commercial availability of TONMYA, a newly FDA-approved fibromyalgia treatment, sparking discussions about its potential impact on patients and the company's future revenue. The community is actively debating the drug's pricing, insurance coverage, and the possibility of a short squeeze, while some express concerns about past dilutions and management. Overall, the focus is on whether TONMYA's launch can drive significant growth for Tonix Pharmaceuticals.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors discuss the potential impact of Berkshire Hathaway's recent stake in the company. Community members are weighing the long-term implications of this investment, particularly regarding Google's AI initiatives and data center infrastructure, as well as the company's valuation relative to its peers. Discussions also involve ad revenue and competition in the AI space.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors digest recent earnings and await potential updates on a U.S. relisting, with the community actively debating the impact of delivery costs on margins and the company's growth strategy. Discussions also revolve around expansion plans, competition with Starbucks, and speculations about a possible acquisition, shaping the sentiment around the stock's future prospects. Investor excitement and frustration mix as they closely monitor the company's progress.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as Berkshire Hathaway revealed a new multi-billion dollar stake, signaling confidence in the tech giant. Community members are discussing the implications of Buffett's investment, particularly regarding Google's position in the AI landscape and potential future growth. The news arrives amid existing discussions around Google's AI investments and infrastructure expansion.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending amid discussions around lithium prices and the company's potential for growth, with some traders highlighting the stock's oversold conditions and potential for a rebound. Community members are debating the impact of production updates, potential acquisitions, and broader sector trends on the stock's future performance. Short sellers and bullish investors are actively exchanging opinions on potential price movements.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending amid analyst upgrades and discussion of its potential role in a TikTok deal, signaling positive momentum for the stock. Community members are weighing the company's prospects in AI and data centers, with some pointing to recent financial target increases and potential for undervaluation. Concerns remain around volatility and achieving all-time highs, despite the positive outlook and AI tailwinds.

Memecoin on Injective taken over by the community.

Nonja

Nonja ($NONJA) is trending as community members highlight its strong fundamentals within the Injective ecosystem, including high burned liquidity, an active community, and successful NFT collections. Bullish sentiment is fueled by Nonja's potential to outperform as Injective gains traction, with many anticipating significant gains. The community emphasizes $NONJA's strong position as a top meme coin on Injective.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

HYMC is trending as investors discuss the company's potential amid rising silver futures and recent news of debt elimination. Community members are encouraged by these factors, contributing to bullish sentiment. Some are also pointing to BlackRock accumulating the stock and its possible impact on partner company AMC.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending following strong Q3 results, including a significant revenue jump and increased backlog, driving optimism about its position in the autonomous drone systems market. The community is focused on the company's growth strategy, potential government contracts, and recent acquisitions, viewing Ondas as a key player in the defense and security sectors. Analyst upgrades and institutional buying are adding to the positive sentiment.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intrust Bank NA Decreases Stake in Merck & Co., Inc. $MRK

Intrust Bank NA decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 17.4% in the second quarter, according to its most recent Form 13F filing with the Securities...

Rothschild Investment LLC Cuts Holdings in Merck & Co., Inc. $MRK

Rothschild Investment LLC reduced its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange...

Nomura Asset Management Co. Ltd. Has $122.30 Million Stake in Merck & Co., Inc. $MRK

Nomura Asset Management Co. Ltd. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 0.4% during the second quarter, according to its most recent filing with the Securities...

Raiffeisen Bank International AG Has $57.28 Million Position in Merck & Co., Inc. $MRK

Raiffeisen Bank International AG lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 26.2% during the 2nd quarter, according to its most recent Form 13F filing with the...

Symphony Financial Ltd. Co. Acquires New Position in Merck & Co., Inc. $MRK

Symphony Financial Ltd. Co. purchased a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund...

Chiron Capital Management LLC Increases Position in Merck & Co., Inc. $MRK

Chiron Capital Management LLC increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 62.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with...

Avantax Advisory Services Inc. Buys 34,861 Shares of Merck & Co., Inc. $MRK

Avantax Advisory Services Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 15.2% during the second quarter, according to its most recent filing with the Securities and...

<ul class="summary-bullets"><li>Merck’s all-cash agreement grants it access to Cidara’s lead flu-prevention antibody, CD388, which has received FDA Breakthrough Therapy designation and is currently in late-stage studies enrolling more than 6,000 participants.</li><li>Major brokerages moved to neutral stances following the announcement.</li><li>Retail traders reacted on Stocktwits, with many celebrating long-held gains.</li></ul><p>Cidara Therapeutics, up more than 700% this year, more than doubled on Friday after Merck unveiled a $9.2 billion all-cash takeover, only for major Wall Street firms to turn neutral on the biotech following the deal’s announcement.</p><p>The deal values Cidara at $221.50 per share, representing a roughly 109% premium to Thursday’s close, and is expected to close in the first quarter of 2026, subject to customary conditions.</p><h2 class="st-heading-2"><strong>Analysts Cut Ratings After Deal Announcement</strong></h2><p>Despite the stock surge, major brokerages shifted to neutral stances across the board. Morgan Stanley downgraded Cidara to ‘Equal Weight’, JPMorgan moved to ‘Neutral’, RBC Capital to ‘Sector Perform’, and Needham shifted to ‘Hold’. H.C. Wainwright also stepped back to ‘Neutral’.&nbsp;</p><h2 class="st-heading-2"><strong>Merck’s Strategic Push Ahead Of Keytruda Patent Expiry</strong></h2><p>Merck said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-to-buy-cidara-in-9.2-billion-dollar-deal/cLPQJxLRE44">the takeover</a> strengthens its respiratory pipeline ahead of the anticipated 2028 patent loss for Keytruda, its top-selling cancer therapy that generated more than $25 billion last year. The move follows Merck’s $10 billion acquisition of Verona Pharma in July, part of a series of large deals aimed at building future revenue streams.</p><p>Cidara brings Merck its lead candidate, CD388, a long-acting antibody designed to prevent influenza infection in high-risk individuals. The U.S. Food and Drug Administration has granted CD388 Breakthrough Therapy designation, potentially speeding its review. The program is currently in late-stage studies across high-risk populations, including immunosuppressed patients who cannot receive seasonal flu vaccines and adults aged 65 and older. More than 6,000 participants are expected to be enrolled globally by the end of the month.</p><h2 class="st-heading-2"><strong>Competitive Bidding And Rising Value</strong></h2><p>Discussions&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cidara-therapeutics-stock-soars-42-after-hours-on-merck-buyout-buzz/cLPfvfZREEh">reportedly</a> extended late into Thursday as Merck faced competition from another pharmaceutical group before its winning bid was selected. The high demand reflects growing interest in long-acting influenza prevention technologies, particularly for vulnerable populations.</p><p><a href="https://stocktwits.com/symbol/CDTX">Cidara</a> has been among the sector’s strongest performers in recent months. Its shares have been fueled by robust clinical data, speculation about a potential auction, and rising interest in CD388’s commercial prospects. The frenzy comes amid a broader wave of pharmaceutical dealmaking, including Pfizer’s recent win over Novo Nordisk in the race for obesity-drug developer Metsera in a deal worth up to $10 billion.</p><h2 class="st-heading-2"><strong>Stocktwits Users Celebrate Big Payday</strong></h2><p>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both seeing elevated message activity ranging from ‘extremely high’ to ‘high’.</p><p>Some users said they had waited a long time for this outcome and thanked the Cidara team as they exited their positions, while others congratulated holders, noting that the deal delivered major gains for many investors.</p><p><stembedurl>https://stocktwits.com/Tauro83/message/636302166</stembedurl></p><p><stembedurl>https://stocktwits.com/Kabita84/message/636294520</stembedurl></p><p><a href="https://stocktwits.com/symbol/MRK">Merck’s stock</a> has declined 4% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover 

Merck’s all-cash agreement grants it access to Cidara’s lead flu-prevention antibody, CD388, which has received FDA Breakthrough Therapy designation and is currently in late-stage studies enrolling more than 6,000 participants.

Equity

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Cidara Therapeutics, Inc. (NasdaqCM: CDTX) to...

Westpac Banking Corp Acquires 3,253 Shares of Merck & Co., Inc. $MRK

Westpac Banking Corp lifted its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$93.51
Prev Close	$92.92
Open	$93.03
Dividend Yield	3.14%
50-Day Moving Average	$85.24
Beta	0.29
Avg. Volume	11.41M
PE Ratio	12.29

52-Week High	$105.07
52-Week Low	$73.31
Market Capitalization	$328.36B
EPS (Annual)	$6.74
Price to Book	4.46
Revenue Per Employee	$852,973.33
Enterprise Value/EBITDA	N/A

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRK News

MRKMerck & Co Inc